Fortress Biotech Inc. (FBIO)
Fortress Biotech Statistics
Share Statistics
Fortress Biotech has 27.6M shares outstanding. The number of shares has increased by 50.22% in one year.
| Shares Outstanding | 27.6M |
| Shares Change (YoY) | 50.22% |
| Shares Change (QoQ) | 3.05% |
| Owned by Institutions (%) | 0.96% |
| Shares Floating | 19.73M |
| Failed to Deliver (FTD) Shares | 51 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 2.62M, so 9.5% of the outstanding shares have been sold short.
| Short Interest | 2.62M |
| Short % of Shares Out | 9.5% |
| Short % of Float | 13.29% |
| Short Ratio (days to cover) | 4.57 |
Valuation Ratios
The PE ratio is -0.4 and the forward PE ratio is -2.05. Fortress Biotech's PEG ratio is 0.01.
| PE Ratio | -0.4 |
| Forward PE | -2.05 |
| PS Ratio | 0.29 |
| Forward PS | 0.2 |
| PB Ratio | 1.08 |
| P/FCF Ratio | -0.18 |
| PEG Ratio | 0.01 |
Enterprise Valuation
Fortress Biotech Inc. has an Enterprise Value (EV) of 32.08M.
| EV / Earnings | -0.53 |
| EV / Sales | 0.38 |
| EV / EBITDA | -0.24 |
| EV / EBIT | -0.23 |
| EV / FCF | -0.24 |
Financial Position
The company has a current ratio of 1.38, with a Debt / Equity ratio of 3.93.
| Current Ratio | 1.38 |
| Quick Ratio | 1.26 |
| Debt / Equity | 3.93 |
| Total Debt / Capitalization | 79.71 |
| Cash Flow / Debt | -1.45 |
| Interest Coverage | -11.95 |
Financial Efficiency
Return on equity (ROE) is -2.69% and return on capital (ROIC) is -158.38%.
| Return on Equity (ROE) | -2.69% |
| Return on Assets (ROA) | -0.36% |
| Return on Capital (ROIC) | -158.38% |
| Revenue Per Employee | $454,370.97 |
| Profits Per Employee | $-326,005.38 |
| Employee Count | 186 |
| Asset Turnover | 0.5 |
| Inventory Turnover | 2.61 |
Taxes
| Income Tax | 521K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -13.5% in the last 52 weeks. The beta is 1.75, so Fortress Biotech's price volatility has been higher than the market average.
| Beta | 1.75 |
| 52-Week Price Change | -13.5% |
| 50-Day Moving Average | 1.72 |
| 200-Day Moving Average | 1.83 |
| Relative Strength Index (RSI) | 53.43 |
| Average Volume (20 Days) | 398.88K |
Income Statement
In the last 12 months, Fortress Biotech had revenue of 84.51M and earned -60.64M in profits. Earnings per share was -8.47.
| Revenue | 84.51M |
| Gross Profit | 57.85M |
| Operating Income | -142.34M |
| Net Income | -60.64M |
| EBITDA | -133.64M |
| EBIT | -142.34M |
| Earnings Per Share (EPS) | -8.47 |
Balance Sheet
The company has 80.93M in cash and 88.59M in debt, giving a net cash position of -7.67M.
| Cash & Cash Equivalents | 80.93M |
| Total Debt | 88.59M |
| Net Cash | -7.67M |
| Retained Earnings | -694.87M |
| Total Assets | 127.08M |
| Working Capital | 15.97M |
Cash Flow
In the last 12 months, operating cash flow was -128.22M and capital expenditures -63K, giving a free cash flow of -136.32M.
| Operating Cash Flow | -128.22M |
| Capital Expenditures | -63K |
| Free Cash Flow | -136.32M |
| FCF Per Share | -16.81 |
Margins
Gross margin is 68.45%, with operating and profit margins of -168.43% and -71.75%.
| Gross Margin | 68.45% |
| Operating Margin | -168.43% |
| Pretax Margin | -181.79% |
| Profit Margin | -71.75% |
| EBITDA Margin | -158.13% |
| EBIT Margin | -168.43% |
| FCF Margin | -161.3% |
Dividends & Yields
FBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -489.6% |
| FCF Yield | -286.28% |
Analyst Forecast
The average price target for FBIO is $21, which is 1113.9% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21 |
| Price Target Difference | 1113.9% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Oct 10, 2023. It was a backward split with a ratio of 1:15.
| Last Split Date | Oct 10, 2023 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -10.23 |
| Piotroski F-Score | 1 |